Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

Inclusion Criteria: * Patient (adult or pediatric) is ≥ 2 years of age * Patient has a physician confirmed/documented diagnosis of PROS * Patient has a documented evidence of a mutation in the PIK3CA gene * Patient's condition was assessed by the treating physician as severe or life threatening and treatment was deemed necessary * Patient has been treated with at least one dose of alpelisib, initiated on or before 23-Sep-2019 (i.e. at least 24 weeks before the cut-off date of the 09-Mar-2020) * Patient has medical chart history available during enrollment in the Novartis MAP * Patient (or parent/guardian in case of pediatric patient) consented to participate in the study (as required by local ethics regulations) Inclusion criteria for MAP enrollment (assessed at the time of alpelisib initiation)